Biotech Regeneron and drug company Bayer have resolved their appeal of a ruling that allowed generic pharmaceutical manufacturer Sandoz to launch a version of top selling macular degeneration drug Eylea.
A judge has declined to order US-based animal genomics company Scidera to file a position statement in its bovine gene patent infringement suit and said she was “running out of patience” after unsuccessful strike-out and summary dismissal applications by the defendants.
Animal drug company Zoetis has lost its bid for summary dismissal of claims that it infringed US-based animal genomics company Scidera’s bovine gene patent, with a judge saying its novel arguments were not so clear-cut and needed to be worked out at trial.
Biotech Regeneron and drug company Bayer have wasted no time in challenging a decision that cleared the way for generic pharmaceutical manufacturer Sandoz to launch a version of top selling Eylea.
Regeneron and Bayer have lost their bid to block generic drug maker Sandoz from launching a biosimilar of their blockbuster eye drug Eylea.
A group of Australia’s leading beef and dairy companies has failed to strike-out a suit alleging their genetic testing system for cattle infringes the patent of a US genomics company, with a judge rejecting objections to the phrase ‘further or in the alternative’.
Bayer has filed a High Court challenge to a decision that invalidated its patents for blockbuster blood thinner Xarelto, saying it would adversely affect drug research and development.
Bayer has lost its battle to protect top-selling blood thinner Xarelto from generic competition, with the Full Court finding two patents for the drug are invalid.
Novartis unit Sandoz AG has filed an appeal after it was was barred from selling a generic version of top-selling blood clot drug Xarelto and failed to revoke two Bayer patents for the drug.
Novartis unit Sandoz AG has lost its bid to revoke Bayer’s patents for its top-selling blood clot drug Xarelto and has been barred from selling generic versions of the medication after a judge found the German pharma giant’s patents were valid.